Literature DB >> 26409302

Anti-high mobility group box 1 monoclonal antibody improves ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy.

Masahiro Sugihara1, Hiroshi Sadamori2, Masahiro Nishibori3, Yasuharu Sato4, Hiroshi Tazawa1, Susumu Shinoura1, Yuzo Umeda1, Ryuichi Yoshida1, Daisuke Nobuoka1, Masashi Utsumi1, Kyotaro Ohno4, Takeshi Nagasaka1, Tadashi Yoshino4, Hideo Kohka Takahashi5, Takahito Yagi1, Toshiyoshi Fujiwara6.   

Abstract

BACKGROUND: The purpose of this study is to determine the effects of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) on ischemia/reperfusion injury (IRI) and the mode of liver regeneration.
METHODS: Rats underwent 70% hepatectomy with IRI caused by clamping the hepatoduodenal ligament for 20 minutes, followed by the administration of anti-HMGB1 mAb immediately before declamping the hepatoduodenal ligament. Five animals were used for each time point. We then evaluated IRI, regeneration parameters and the status of HMGB1 in remnant livers.
RESULTS: The anti-HMGB1 mAb significantly ameliorated the degree of IRI in the remnant livers in association with the downregulation of HMGB1 protein. The ratio of Ki67-positive hepatocytes at 48 hours after 70% hepatectomy was significantly improved. Mean hepatocyte size was significantly reduced and cyclin-dependent kinase inhibitor 1 expression was significantly attenuated.
CONCLUSIONS: Anti-HMGB1 mAb ameliorated IRI and improved the mode of liver regeneration after IRI followed by 70% hepatectomy in rats.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatectomy; High mobility group box 1; Ischemia/reperfusion injury; Liver regeneration

Mesh:

Substances:

Year:  2015        PMID: 26409302     DOI: 10.1016/j.amjsurg.2015.06.025

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

Review 1.  Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19.

Authors:  M Nishibori
Journal:  J Pharmacol Sci       Date:  2022-06-15       Impact factor: 3.578

2.  Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice.

Authors:  Li Fu; Keyue Liu; Hidenori Wake; Kiyoshi Teshigawara; Tadashi Yoshino; Hideo Takahashi; Shuji Mori; Masahiro Nishibori
Journal:  Sci Rep       Date:  2017-04-26       Impact factor: 4.379

3.  Subcutaneous Inoculation of Echinococcus multilocularis Induces Delayed Regeneration after Partial Hepatectomy.

Authors:  Shadike Apaer; Tuerhongjiang Tuxun; Heng Zhang; Amina Aierken; Tao Li; Jin-Ming Zhao; Hao Wen
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

4.  The role of dendritic cells regulated by HMGB1/TLR4 signalling pathway in myocardial ischaemia reperfusion injury.

Authors:  Jiyang Xue; Hanwei Ge; Zhiyong Lin; Hanlei Wang; Wei Lin; Yong Liu; Guowei Wu; Jie Xia; Qifeng Zhao
Journal:  J Cell Mol Med       Date:  2019-02-19       Impact factor: 5.310

5.  Remote Ischemic Preconditioning and Diazoxide Protect from Hepatic Ischemic Reperfusion Injury by Inhibiting HMGB1-Induced TLR4/MyD88/NF-κB Signaling.

Authors:  Won Uk Koh; Jiye Kim; Jooyoung Lee; Gi-Won Song; Gyu Sam Hwang; Eunyoung Tak; Jun-Gol Song
Journal:  Int J Mol Sci       Date:  2019-11-24       Impact factor: 5.923

6.  Ac2‑26 alleviates hepatic ischemia‑reperfusion injury based on inhibiting the positive feedback loop of HMGB1/TLR4/NF‑κB/neutrophils.

Authors:  Chen Bai; Zhengchen Jiang; Hongxin Jiang; Shuna Yu; Ming Li; Fangfang Chu; Yaxin Sheng; Jianguo Li; Jiying Jiang; Wanzhen Li
Journal:  Exp Ther Med       Date:  2022-09-14       Impact factor: 2.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.